切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2020, Vol. 14 ›› Issue (12) : 981 -987. doi: 10.3877/cma.j.issn.1674-0785.2020.12.006

所属专题: 乳腺疾病 文献

临床研究

错配修复蛋白表达与乳腺癌新辅助化疗效果的关系
李诚1, 蔡园园2, 韩桂燕3, 王楠2, 王慧3, 张玉萍3, 王明臣2, 郝福荣4,(), 张云香3   
  1. 1. 作者单位;264003 山东烟台,烟台毓璜顶医院莱山分院放疗科
    2. 261041 山东潍坊,潍坊市人民医院放疗科
    3. 261041 山东潍坊,潍坊市人民医院病理科
    4. 261041 山东潍坊,潍坊市人民医院放疗科;261041 山东潍坊,潍坊市放射物理与肿瘤放射生物学重点实验室
  • 收稿日期:2020-06-27 出版日期:2020-12-15
  • 通信作者: 郝福荣
  • 基金资助:
    山东省自然科学基金(ZR2009CM081)

Association between MMR protein expression and efficacy of neoadjuvant chemotherapy in breast cancer

Cheng Li1, Yuanyuan Cai2, Guiyan Han3, Nan Wang2, Hui Wang3, Yuping Zhang3, Mingchen Wang2, Furong Hao4,(), Yunxiang Zhang3   

  1. 1. Department of Radiation Oncology, Laishan Branch of Yantai Yuhuangding Hospital, Yantai 264003, China;
    2. Department of Radiation Oncology, Weifang People's Hospital, Weifang 261041, China
    3. Department of Pathology, Weifang People's Hospital, Weifang 261041, China
    4. Department of Radiation Oncology, Weifang People's Hospital, Weifang 261041, China; Department of Pathology, Weifang People's Hospital, Weifang 261041, China
  • Received:2020-06-27 Published:2020-12-15
  • Corresponding author: Furong Hao
引用本文:

李诚, 蔡园园, 韩桂燕, 王楠, 王慧, 张玉萍, 王明臣, 郝福荣, 张云香. 错配修复蛋白表达与乳腺癌新辅助化疗效果的关系[J/OL]. 中华临床医师杂志(电子版), 2020, 14(12): 981-987.

Cheng Li, Yuanyuan Cai, Guiyan Han, Nan Wang, Hui Wang, Yuping Zhang, Mingchen Wang, Furong Hao, Yunxiang Zhang. Association between MMR protein expression and efficacy of neoadjuvant chemotherapy in breast cancer[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(12): 981-987.

目的

探究错配修复(MMR)蛋白表达与乳腺癌新辅助化疗(NACT)疗效的关系。

方法

收集潍坊市人民医院2016年1月1日至2018年10月31日53例行NACT治疗的乳腺癌患者临床病理资料,采用组织芯片(TMAs)技术、免疫组织化学(IHC)方法检测NACT前乳腺癌组织4种MMR蛋白(MSH2、MSH6、PMS2、MLH1)表达水平。Miller/Payne分级G5定义为病理完全缓解(pCR),G2~4定义为部分缓解(PR),G1定义为稳定(SD)。应用SPSS 22.0软件进行数据统计分析。

结果

53例乳腺癌患者NACT疗效:pCR(G5)10例(18.9%),PR(G2~4)36例(67.9%),SD(G1)7例(13.2%)。IHC结果显示:53例患者MSH2、MSH6、PMS2、MLH1蛋白均表达阳性,未发现错配修复缺陷患者。患者各临床T分期间MSH6蛋白表达强度构成比具有统计学差异(χ2=6.09,P=0.04),患者各年龄、月经状态、临床T分期、淋巴结状态、雌激素受体、孕激素受体、人表皮生长因子受体2、Ki-67指数、分子分型间MSH2、PMS2及MLH1蛋白表达强度构成比差异均无统计学意义(P>0.05)。乳腺癌NACT疗效与MLH1(r=0.40,P=0.00)、MSH6(r=0.37,P=0.01)蛋白表达强度呈正相关关系,而与MSH2、PMS2蛋白表达强度无相关性(P>0.05)。

结论

乳腺癌活检组织MSH6、MLH1蛋白表达增强提示更好的NACT疗效,值得进一步研究。

Objective

To investigate the association between the efficacy of neoadjuvant chemotherapy (NACT) and the expression of mismatch repair (MMR) proteins in breast cancer.

Methods

The clinicopathological data of 53 breast cancer patients treated with NACT from January 1, 2016 to October 31, 2018 in Weifang People's Hospital were collected, and MMR (MSH2, MSH6, PMS2, and MLH1) in pretreatment biopsies of these patients were assessed by immunohistochemistry (IHC) in tissue microarrays (TMAs). Responses to NACT were classified as pathological complete response (pCR; grade 5), partial response (PR; grades 2-4), and stable disease (SD; grade 1) according to the Miller/Payne system. The results were analyzed using SPSS 22.0 statistical software.

Results

Of the 53 breast cancer patients included, 10 (18.9%) achieved pCR (G5), 36 (67.9%) achieved PR (G2-4), and 7 (13.2%) achieved SD (G1). IHC analysis revealed that MSH2, MSH6, PMS2, and MLH1 proteins were all expressed positively in the 53 breast cancer patients and none of them were MMR-deficient. In terms of the relationship with tumor stage, the expression of MSH6 showed a statistical difference among different clinical stages (χ2=6.09, P=0.04). Age, menstrual status, clinical tumor stage, nodal status, ER, PR, HER2, Ki-67, and molecular subtypes had no significant association with the expression of MSH2, PMS2, and MLH1 (P>0.05). The efficacy of NACT was positively associated with MLH1 (r=0.40, P=0.00) or MSH6 (r=0.37, P=0.01) expression. There was no correlation between the efficacy of NACT and MSH2 or PMS2 (P>0.05) expression.

Conclusion

Increased expression of MSH6 and MLH1 in pretreatment biopsies of breast cancer patients suggests better efficacy of NACT.

图1 乳腺癌新辅助化疗前MSH2、MSH6、PMS2、MLH1蛋白表达强度(SP,×400)
表1 乳腺癌新辅助化疗前MMR蛋白表达的临床特征分布及构成比分析(例,n=53)
表2 53例乳腺癌新辅助化疗前MMR蛋白表达与新辅助化疗疗效的相关性[例(%)]
1
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析 [J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
2
Puig CA, Hoskin TL, Day CN, et al. National trends in the use of neoadjuvant chemotherapy for hormone receptor-negative breast cancer: a national cancer data base study [J]. Ann Surg Oncol, 2017, 24(5): 1242-1250.
3
Spring L, Greenup R, Niemierko A, et al. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer [J]. J Natl Compr Canc Netw, 2017, 15(10): 1216-1223.
4
LeVasseur N, Sun J, Gondara L, et al. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis [J]. J Cancer Res Clin Oncol, 2020, 146(2): 529-536.
5
Gupta D,Heinen CD. The mismatch repair-dependent DNA damage response: Mechanisms and implications [J]. DNA Repair (Amst), 2019, 78: 60-69.
6
Zaanan A, Shi Q, Taieb J, et al. Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy: a pooled analysis from 2 randomized clinical trials [J]. JAMA Oncol, 2018, 4(3): 379-383.
7
邱春华, 张志宏, 董丹丹, 等. 错配修复基因蛋白在结直肠癌诊治中的临床应用 [J]. 中国肿瘤临床, 2018, 45(19): 39-42.
8
Roberts ME, Jackson SA, Susswein LR, et al. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer [J]. Genet Med, 2018, 20(10): 1167-1174.
9
Cheng AS, Leung SCY, Gao D, et al. Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort [J]. Breast Cancer Res Treat, 2020, 179(1): 3-10.
10
Davies H, Morganella S, Purdie CA, et al. Whole-genome sequencing reveals breast cancers with mismatch repair deficiency [J]. Cancer Res, 2017, 77(18): 4755-4762.
11
Fusco N, Lopez G, Corti C, et al. Mismatch repair protein loss as a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability [J]. JNCI Cancer Spectr, 2018, 2(4): pky056.
12
王敬华, 郑美珠,李永清. 乳腺癌免疫组化分子分型与新辅助化疗疗效相关性分析 [J]. 中华肿瘤防治杂志, 2018, 25(10): 704-708.
13
徐乘骏, 张朝蓬, 邱恒, 等. 分子分型对乳腺癌新辅助化疗后肿瘤退缩模式的影响 [J]. 中国肿瘤临床, 2018, 45(17): 894-897.
14
Kheirelseid EA, Miller N, Chang KH, et al. Mismatch repair protein expression in colorectal cancer [J]. J Gastrointest Oncol, 2013, 4(4): 397-408.
15
Malik SS, Masood N, Asif M, et al. Expressional analysis of MLH1 and MSH2 in breast cancer [J]. Curr Probl Cancer, 2019, 43(2): 97-105.
16
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011 [J]. Ann Oncol, 2011, 22(8): 1736-1747.
17
Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J]. Breast, 2003, 12(5): 320-327.
18
晋龙, 眭玉霞, 王丽萍, 等. 结直肠癌错配修复蛋白MLH1、MSH2、MSH6及PMS2表达与临床病理特征的关系 [J]. 诊断病理学杂志, 2017, 24(11): 813-817.
19
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [J]. Science, 2017, 357(6349): 409-413.
20
Mills AM, Dill EA, Moskaluk CA, et al. The relationship between mismatch repair deficiency and PD-L1 expression in breast carcinoma [J]. Am J Surg Pathol, 2018, 42(2): 183-191.
21
计骏, 陈国庭, 于颖彦, 等. 错配修复基因hMSH2在乳腺癌中的表达及意义 [J]. 中国癌症杂志, 2002, 12(6): 101-102.
22
徐玲玉, 江勇. hMSH2、hMLH1和p53在乳腺癌的表达及临床意义 [J]. 江苏医药, 2015, 41(24): 2972-2974+3083.
23
Li XB, Krishnamurti U, Bhattarai S, et al. Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer [J]. Am J Clin Pathol, 2016, 145(6): 871-878.
24
Wu Z, Zhang L, Peng J, et al. Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting [J]. Cancer Biol Ther, 2019, 20(6): 941-947.
25
Santarpia L, Iwamoto T, Di Leo A, et al. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes [J]. The Oncologist, 2013, 18(10): 1063-1073.
26
Fedier A, Schwarz VA, Walt H, et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair [J]. Int J Cancer, 2001, 93(4): 571-576.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[3] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[4] 黄程鑫, 陈莉, 刘伊楚, 王水良, 赖晓凤. OPA1 在乳腺癌组织的表达特征及在ER阳性乳腺癌细胞中的生物学功能研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 275-284.
[5] 张昊, 潘卫东. 胰腺癌新辅助化疗后可切除性评估现状及进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 629-633.
[6] 王军华, 王锐炫. 胰腺癌新辅助化疗现状和治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 640-643.
[7] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[8] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[9] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[10] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[11] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[13] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
阅读次数
全文


摘要